Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
Compass Therapeutics presented Phase 1 data for its PD-1/PD-L1 bispecific antibody CTX-8371 at the 2026 ASCO Annual Meeting, showing promising activity in patients with advanced malignancies resistant to prior checkpoint inhibitors. The study observed deep and durable responses in triple-negative breast cancer, Hodgkin lymphoma, and non-small cell lung cancer, with an overall response rate of 33% at the two highest dose levels.
Key figures
- Drug Name
- CTX-8371
- Phase Of Trial
- Phase 1
- Dose levels
- 3.0 and 10.0 mg/kg
- Patients evaluated
- 15
- Hl response durability
- 7.5+ months
- Tnbc response durability
- 10.5+ months
- Overall response rate high dose
- 33%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.